Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of a VEGF antagonist to treat angiogenic eye disorders

Use of a VEGF antagonist to treat angiogenic eye disorders

US Patent 11975045 · Granted May 7, 2024

Estimated economic value: $253,657,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments2025
Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof2025
EGFR x CD28 multispecific antibodies2025
Genetically modified mice and engraftment2025
Use of a VEGF antagonist to treat angiogenic eye disorders2025
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments2025
High affinity human antibodies to human IL-4 receptor2024
Humanized M-CSF mice2024
Genetically modified non-human animals and methods of use thereof2024
Targeted modification of rat genome2024
Use of a VEGF antagonist to treat angiogenic eye disorders2024
Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treati2024